EpilepsyBridgeNCT07909460
Blood Brain Barrier Dysfunction in Glioma and Epileptogenesis
An observational study of Epilepsy and Glioma, run by University College, London.
Trial summary
Gliomas are the most common and deadliest primary brain tumours in children and adults. Many people with glioma also develop epilepsy, which can be difficult to treat. Research suggests that inflammation in the brain and shared disease pathways may contribute to both glioma and epilepsy. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- How many people
- 56 participants
- Where
- No sites listed yet
- Study dates
- 4 Jan 2027to 4 Jan 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study will include adults with glioma located in the frontal or temporal regions of the brain, with or without tumour-related epilepsy, and healthy control participants without glioma or epilepsy. The planned main study groups comprise 19 participants with glioma and epilepsy, 19 participants with glioma without epilepsy, and 18 healthy controls. Patients will be identified through the neuro-oncology clinic at Barts Health NHS Trust and approached by their treating consultants. Healthy controls will be recruited from existing volunteer pools at participating centres and through interested friends or relatives of patients who contact the research team directly.
Who may be able to join
- diagnosis of glioma based on neuro-imaging findings
- able to give informed consent
- Male or female between age 18-65 years;
- for epilepsy patients: confirmed diagnosis of glioma-related epilepsy
- for controls: no history of glioma or epilepsy
Who cannot join
- no recent tonic-clonic seizure (within 24 hours)
- pregnancy
- any metal objects in the body, e.g. cardiac pacemaker, vagal nerve stimulator (VNS) or other electronic device or ferromagnetic metal foreign bodies
- Inability to undergo MRI scan, e.g. claustrophobia
- Unwillingness or inability to give informed consent
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: BLOOD BRAIN BARRIER DYSFUNCTION IN GLIOMA AND EPILEPTOGENESIS
Gliomas are the most common and deadliest primary brain tumours in children and adults. Many people with glioma also develop epilepsy, which can be difficult to treat. Research suggests that inflammation in the brain and shared disease pathways may contribute to both glioma and epilepsy. Seizure-related electrical activity may also promote tumour growth and spread.
This study aims to investigate the relationship between blood-brain barrier (BBB) dysfunction, glioma and epilepsy. The BBB normally protects the brain by regulating the movement of substances from the blood into brain tissue. Increased leakage across the BBB may indicate inflammation and may contribute to changes in brain structure and function.
Read more
Using a recently developed brain imaging technique, the study will measure BBB leakage in people with glioma, including those with and without tumour-related epilepsy, and in control participants without glioma or epilepsy. The researchers will compare imaging findings between these groups to investigate whether BBB leakage is associated with glioma and epilepsy, and whether it may be linked to structural changes in the brain.
The study will also examine whether the extent of BBB leakage is associated with tumour subtype and grade, and whether this imaging technique could help identify and characterise brain tumours. Finally, the researchers will compare the new imaging technique with conventional contrast-enhanced magnetic resonance imaging (MRI) to assess its ability to detect subtle BBB leakage.
The findings may improve understanding of the relationship between BBB dysfunction, glioma and epilepsy, and help establish the potential value of advanced brain imaging in the diagnosis and assessment of gliomas.
- Keywords
- blood brain barrier, MRI, epilepsy, brain tumour
- Medical subject headings
- Epilepsy, Glioma, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Glioma with epilepsy | participants with glioma and tumour-related epilepsy. | |
| Glioma without epilepsy | participants with glioma who do not have epilepsy. | |
| control group | participants without glioma or epilepsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences in inflammatory markers in people with glioma and healthy controls, as well as between people with glioma with and without epilepsy.
inflammatory markers will be defined as blood brain barrier leakage using filter exchange imaging
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study start4 Jan 2027 (estimated)
- Primary completion4 Jan 2029 (estimated)
- Study completion4 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 56 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07909460
- Sponsor's protocol ID
- 179198
- Acronym
- Bridge
- Status last verified
- Oct 2026
- First submitted
- 20 Oct 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BLOOD BRAIN BARRIER DYSFUNCTION IN GLIOMA AND EPILEPTOGENESIS
- ClinicalTrials.gov ID
- NCT07909460
- Acronym / sponsor ID
- Bridge / 179198
- Keywords
- blood brain barrier, MRI, epilepsy, brain tumour
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 56 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Study start
- 4 Jan 2027 (estimated)
- Primary completion
- 4 Jan 2029 (estimated)
- Study completion
- 4 Jan 2030 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Gliomas are the most common and deadliest primary brain tumours in children and adults. Many people with glioma also develop epilepsy, which can be difficult to treat. Research suggests that inflammation in the brain and shared disease pathways may contribute to both glioma and epilepsy. Seizure-related electrical activity may also promote tumour growth and spread.
This study aims to investigate the relationship between blood-brain barrier (BBB) dysfunction, glioma and epilepsy. The BBB normally protects the brain by regulating the movement of substances from the blood into brain tissue. Increased leakage across the BBB may indicate inflammation and may contribute to changes in brain structure and function.
Using a recently developed brain imaging technique, the study will measure BBB leakage in people with glioma, including those with and without tumour-related epilepsy, and in control participants without glioma or epilepsy. The researchers will compare imaging findings between these groups to investigate whether BBB leakage is associated with glioma and epilepsy, and whether it may be linked to structural changes in the brain.
The study will also examine whether the extent of BBB leakage is associated with tumour subtype and grade, and whether this imaging technique could help identify and characterise brain tumours. Finally, the researchers will compare the new imaging technique with conventional contrast-enhanced magnetic resonance imaging (MRI) to assess its ability to detect subtle BBB leakage.
The findings may improve understanding of the relationship between BBB dysfunction, glioma and epilepsy, and help establish the potential value of advanced brain imaging in the diagnosis and assessment of gliomas.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Glioma with epilepsy | – | –participants with glioma and tumour-related epilepsy. |
| Glioma without epilepsy | – | –participants with glioma who do not have epilepsy. |
| control group | – | –participants without glioma or epilepsy |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study will include adults with glioma located in the frontal or temporal regions of the brain, with or without tumour-related epilepsy, and healthy control participants without glioma or epilepsy. The planned main study groups comprise 19 participants with glioma and epilepsy, 19 participants with glioma without epilepsy, and 18 healthy controls. Patients will be identified through the neuro-oncology clinic at Barts Health NHS Trust and approached by their treating consultants. Healthy controls will be recruited from existing volunteer pools at participating centres and through interested friends or relatives of patients who contact the research team directly.
Key inclusion criteria (5 listed)
- diagnosis of glioma based on neuro-imaging findings
- able to give informed consent
- Male or female between age 18-65 years;
- for epilepsy patients: confirmed diagnosis of glioma-related epilepsy
- for controls: no history of glioma or epilepsy
Key exclusion criteria (5 listed)
- no recent tonic-clonic seizure (within 24 hours)
- pregnancy
- any metal objects in the body, e.g. cardiac pacemaker, vagal nerve stimulator (VNS) or other electronic device or ferromagnetic metal foreign bodies
- Inability to undergo MRI scan, e.g. claustrophobia
- Unwillingness or inability to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Differences in inflammatory markers in people with glioma and healthy controls, as well as between people with glioma with and without epilepsy.
Time frame: baseline
inflammatory markers will be defined as blood brain barrier leakage using filter exchange imaging
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Epilepsy and Glioma, run by University College, London.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Britta Wandschneider, MD, PhD (00442034488619, b.wandschneider@ucl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences in inflammatory markers in people with glioma and healthy controls, as well as between people with glioma with and without epilepsy. (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.